Bookmark

Add to MyYahoo RSS

Gilead Sciences News

News on Gilead Sciences (Ticker: GILD) continually updated from thousands of sources around the net.

10 hrs ago | AmericanBankingNews.com

RBC Capital Increases Gilead Sciences Price Target to $115.00

The firm currently has an "outperform" rating on the stock. RBC Capital's price target points to a potential upside of 10.62% from the company's current price.

Comment?

Related Topix: Biotech, Startups, Medicine, Gilead Sciences, CGI Pharmaceuticals, Healthcare Industry

Thu Aug 21, 2014

TheStreet.com

Jim Cramer's Stop Trading: Don't Worry About Gilead Sciences

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals, Mozilla, TheStreetcom, Media, TheStreet, Computers

Wed Aug 20, 2014

AmericanBankingNews.com

Recent Analysts' Ratings Updates for Gilead Sciences

A number of stock research firms have changed their ratings and price targets for Gilead Sciences during the last seven days: Gilead Sciences is now covered by analysts at Argus.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals

Foster's Daily Democrat

$1,000 Sovaldi now hepatitis treatment of choice

The price is sky-high, but so is demand. A new $1,000-per-pill drug has become the treatment of choice for Americans with hepatitis C, a liver-wasting disease that affects more than 3 million.

Comment?

Related Topix: Hepatitis, Medicine, Health, Biotech, Gilead Sciences, Healthcare Industry, Startups, Health Insurance, Medicaid

Mon Aug 18, 2014

Investopedia

4 Large-Cap Healthcare Stocks To Watch

Healthcare has been one of the hottest sectors over the last year and continues to find new highs.

Comment?

Related Topix: Financial Markets, Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups

Sat Aug 16, 2014

Knoxville News Sentinel

David Moon: Breakthrough pill presents puzzle The U.S. Centers for...

The U.S. Centers for Disease Control and Prevention estimates there are 3.2 million Americans with chronic hepatitis C, 17,000 of whom will die this year as a result of the infection - a number that exceeds the annual deaths from HIV/AIDS in the U.S. Fortunately, Gilead Sciences produces a new breakthrough drug, Sovaldi, which has proved to cure 90 ... (more)

Comment?

Related Topix: Centers for Disease Control and Prevention, Gilead Sciences, Biotech, Medicine, Healthcare Industry, Startups, US News, US Senate, Ron Wyden, Democrat, US Politics, Republican, Chuck Grassley, Sports

PR-inside.com

New Market Research Report: Pharmasset, Inc - Pharmaceuticals &...

The company is engaged in discovering, producing and commercializing medicines to treat viral infections.

Comment?

Related Topix: Pharmaceuticals, Pharmasset, Hepatitis, Medicine, Health, Biotech, Gilead Sciences, Healthcare Industry, Startups

Fri Aug 15, 2014

Seeking Alpha

Gilead: Rising Short Interest Provides Yet Another Reason To Own The Stock

Its forward P/E is low relative to the market, thus incorporating caution about the sustainability of profits from its hepatitis C franchise.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals, Pharmaceuticals, Pharmasset

SchaeffersResearch.com

Analyst Update: J C Penney Company Inc, Monster Beverage Corp, and Gilead Sciences, Inc.

However, J.P. Morgan Securities raised its price target on JCP to $11 from $9, representing an unusually bullish forecast for the stock.

Comment?

Related Topix: JC Penney, Biotech, Retail, Medicine, Gilead Sciences, Healthcare Industry, Monster Worldwide, Startups, Human Resources, Advertising, Day Trading, Financial Markets, Personal Finance

Business Journal

Gilead beats back Roche, wins U.K. victory for hepatitis C drug Sovaldi

An arbitration panel ruled Friday that the Foster City-based drug maker's hepatitis C blockbuster Sovaldi did not infringe a 2004 research deal that rival Roche had with Pharmasset Inc. Gilead , led by Chairman and CEO John Martin , bought Pharmasset in 2012 for $11 billion, landing the drug that would become Sovaldi.

Comment?

Related Topix: Startups, Biotech, Medicine, Gilead Sciences, Healthcare Industry, Pharmaceuticals, Pharmasset, Genentech

Seeking Alpha

Gilead: More Good News For This Biotech Juggernaut

Highlighted below is my rebuttal to a recent short thesis on Gilead and why is stock is still cheap and going much higher.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals

BioSpace

Gilead Sciences, Inc. Shaky As Achillion Pharmaceuticals, Inc.'s...

Achillion Pharmaceuticals, Inc. today announced interim results from an ongoing Phase 2 proxy study evaluating ACH-3102, Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-naA ve genotype 1 chronic hepatitis C virus infection.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Achillion Pharmaceuticals, Pharmaceuticals

Wall Street Journal

Gilead Notches Victory in Sovaldi Tussle

Gilead Sciences Inc. on Friday said it scored a key victory in the pharmaceutical industry's competition for hepatitis-C treatment supremacy, as an arbitration panel ruled in its favor over Roche Holding AG's claim to exclusive rights to a lucrative drug.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups

Wall Street Journal

U.K. Drug Panel Endorses Sovaldi

The U.K. agency that evaluates the cost-effectiveness of drugs has recommended that the English health system pay for the controversial Sovaldi hepatitis C treatment sold by Gilead Sciences Inc. Sovaldi can cure nine out of 10 patients with the most common form of hepatitis C, studies have shown, avoiding the need for more costly...

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Opinion

Tue Aug 12, 2014

Seeking Alpha

Cramer's Lightning Round - El Pollo Loco Is Acting Crazy

StoneMor Partners : "I don't understand why it yields 10%. That would usually be a red flag, but I like StoneMor."

Comment?

Related Topix: Biotech, Startups, Medicine, Gilead Sciences, CGI Pharmaceuticals, Healthcare Industry

Mon Aug 11, 2014

TheStreet.com

Why Gilead Sciences (GILD) Stock Is Rising Today

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Mozilla, Financial Markets, TheStreet

Thu Aug 07, 2014

AmericanBankingNews.com

Zacks Downgrades Gilead Sciences to Neutral

They currently have a $97.00 target price on the stock. Zacks 's price objective suggests a potential upside of 5.13% from the stock's previous close.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals

Wed Aug 06, 2014

AmericanBankingNews.com

Zacks Downgrades Gilead Sciences to Neutral

They currently have a $97.00 target price on the stock. Zacks 's price objective suggests a potential upside of 5.13% from the stock's previous close.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals

Tue Aug 05, 2014

AmericanBankingNews.com

Insider Selling: Gilead Sciences EVP Sells 33,000 Shares of Stock

Gilead Sciences EVP Gregg H. Alton sold 33,000 shares of the stock on the open market in a transaction that occurred on Friday, August 1st.

Comment?

Related Topix: Biotech, Startups, Medicine, Gilead Sciences, Healthcare Industry

Seeking Alpha

Has Gilead Priced Sovaldi Too High?

In December 2013, the U.S. Food and Drug Administration approved Gilead Sciences Inc.'s Sovaldia for the treatment of chronic hepatitis C. In a short period of time, Sovaldi has become a treatment of choice for hepatitis.

Comment?

Related Topix: Gilead Sciences, Biotech, Medicine, Healthcare Industry, Hepatitis, Health, Startups, Food and Drug Administration

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••